Relmada Therapeutics, Inc. RLMD Cash ratio
Cash ratio at other companies
Other financials
Where this comes from
Calculated from Relmada Therapeutics, Inc.’s reported figures.
Based on the most recent quarter.
The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s cash ratio.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s cash ratio?
- Relmada Therapeutics, Inc. (RLMD) reported cash ratio of 0.8× in Q1 2026.
- How has Relmada Therapeutics, Inc.'s cash ratio changed year-over-year?
- Relmada Therapeutics, Inc.'s cash ratio increased by 245.0% year-over-year, from 0.2× to 0.8×.
- What is the long-term trend for Relmada Therapeutics, Inc.'s cash ratio?
- Over 5 years (2020 to 2025), Relmada Therapeutics, Inc.'s cash ratio has grown at a 22.4% compound annual growth rate (CAGR), from 0.2× to 0.5×.
- What does cash ratio mean?
- Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.